✦ LIBER ✦

RAD51Cgermline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families

✍ Scribed by Ana Blanco,Sara Gutiérrez-Enríquez…

Book ID: 126353424
Publisher: Springer US
Year: 2014
Tongue: English
Weight: 285 KB
Volume: 147
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-014-3078-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

RAD51Cgermline mutations in Chinese wome

RAD51Cgermline mutations in Chinese women with familial breast cancer

✍ Zhiyuan Pang; Lu Yao; Juan Zhang; Tao Ouyang; Jinfeng Li; Tianfeng Wang; Zhaoqin 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 141 KB

Pathological features of breast and ovar

Pathological features of breast and ovarian cancers inRAD51Cgermline mutation carriers

✍ Heidrun Gevensleben,Verena Bossung,Alfons Meindl… 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 107 KB

DeleteriousRAD51Cgermline mutations rare

DeleteriousRAD51Cgermline mutations rarely predispose to breast and ovarian cancer in Pakistan

✍ Rashid, Muhammad U.; Muhammad, Noor; Faisal, Saima; Amin, Asim; Hamann, Ute 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 289 KB

RAD51C germline mutations in breast and

RAD51C germline mutations in breast and ovarian cancer patients

✍ Mohammad R Akbari, Patricia Tonin, William D Foulkes… 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 115 KB

Analysis of RAD51C germline mutations in

Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients

✍ ER Thompson; SE Boyle; J Johnson; GL Ryland; S Sawyer; DY Choong; kConFab; G Che 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 80 KB

Analysis of RAD51C germline mutations in

Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients

✍ Ella R. Thompson; Samantha E. Boyle; Julie Johnson; Georgina L. Ryland; Sarah Sa 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB

There is strong evidence that overtly inactivating mutations in RAD51C predispose to hereditary breast and ovarian cancer but the prevalence of such mutations, and whether they are associated with a particular clinical phenotype, remains unclear. Resolving these questions has important implications